ASHLEY GARRETT: Open Payments
NPI 1275077034 · SAINT LOUIS, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,621 in 154 payments from 18 companies in 2025. Trend: 2023 $2,289 · 2024 $2,979 · 2025 $2,621
Food & beverage: $2,610Education: $10
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 58 | $923 |
| Janssen Biotech, Inc. | 16 | $297 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 13 | $255 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $194 |
| PFIZER INC. | 12 | $166 |
| GENZYME CORPORATION | 6 | $139 |
| Lilly USA, LLC | 6 | $109 |
| Gilead Sciences, Inc. | 4 | $88 |
| Madrigal Pharmaceuticals | 5 | $81 |
| QOL Medical, LLC | 4 | $75 |
Products named: RINVOQ, TREMFYA, XIFAXAN, LINZESS, ENTYVIO, DUPIXENT, CREON, SKYRIZI.
Industry payments across MO — which companies pay providers there.
